| A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples G Ellison, E Donald, G McWalter, L Knight, L Fletcher, J Sherwood, ... Journal of Experimental & Clinical Cancer Research 29, 1-8, 2010 | 179 | 2010 |
| Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC) JL Sherwood, C Corcoran, H Brown, AD Sharpe, M Musilova, ... PLoS ONE 11 (2), e0150197, 2016 | 177 | 2016 |
| Ultrasensitive detection of multiplexed somatic mutations using MALDI-TOF mass spectrometry MJ Mosko, AA Nakorchevsky, E Flores, H Metzler, M Ehrich, ... The journal of molecular diagnostics 18 (1), 23-31, 2016 | 93 | 2016 |
| Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster A Alfirevic, T Mills, P Harrington, T Pinel, J Sherwood, A Jawaid, JC Smith, ... Pharmacogenetics and genomics 16 (4), 287-296, 2006 | 73 | 2006 |
| Tacrine-induced liver damage: an analysis of 19 candidate genes A Alfirevic, T Mills, D Carr, BJ Barratt, A Jawaid, J Sherwood, JC Smith, ... Pharmacogenetics and genomics 17 (12), 1091-1100, 2007 | 68 | 2007 |
| Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature … J Sherwood, S Dearden, M Ratcliffe, J Walker Journal of Experimental & Clinical Cancer Research 34, 92, 2015 | 67 | 2015 |
| Molecular and genetic association of interleukin-6 in tacrine-induced hepatotoxicity DF Carr, A Alfirevic, JD Tugwood, BJ Barratt, J Sherwood, J Smith, ... Pharmacogenetics and genomics 17 (11), 961-972, 2007 | 39 | 2007 |
| Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice JL Sherwood, H Brown, A Rettino, A Schreieck, G Clark, B Claes, ... ESMO Open 2 (4), e000235, 2017 | 18 | 2017 |
| Panel based MALDI-TOF tumour profiling is a sensitive method for detecting mutations in clinical non small cell lung cancer tumour JL Sherwood, S Müller, MCM Orr, MJ Ratcliffe, J Walker PLoS One 9 (6), e100566, 2014 | 14 | 2014 |
| Method for evaluating patients for treatment with drugs targeting ret receptor tyrosine kinase AJ Ryan, J Sherwood, A Wookey US Patent App. 12/438,306, 2011 | 13 | 2011 |
| Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition T Vaclova, A Chakraborty, J Sherwood, S Ross, D Carroll, JC Barrett, ... Scientific Reports 12 (1), 2699, 2022 | 10 | 2022 |
| Association between serious carbamazepine hypersensitivity reactions and the HSP70 gene cluster A Alfirevic, T Mills, P Harrington, T Pinel, J Sherwood, A Jawaid, JC Smith, ... Toxicology 213 (3), 264-265, 2005 | 4 | 2005 |
| A novel automated SARS-CoV-2 saliva PCR test protects a global asymptomatic workforce N Carter, M Clausen, RA Halpin, C Blackmore, K Cai, O Delpuech, ... Nature Scientific Reports 11 (1), 12676, 2021 | 2 | 2021 |
| Implications of Key Differences Across 12 KRAS Mutation Detection Technologies and Their Relevance in Clinical Practice JL Sherwood, H Brown, A Rettino, A Schreieck, G Clark, B Claes, ... European Society for Medical Oncology, 2016 | 1 | 2016 |
| Circulating free DNA as a surrogate for tumor material for EGFR and KRAS analysis G Ellison, J Sherwood, C Gokhale, A Wallace, R Elles, A Ryan Clinical Cancer Research 16 (19_Supplement), PR4-PR4, 2010 | 1 | 2010 |
| AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: two randomized phase I trials J Armisen, M Rauschecker, J Sarv, M Liljeblad, L Wernevik, M Niazi, ... Journal of Hepatology 10, 1016, 2025 | | 2025 |
| Response: Concerns with conclusions in the article by Sherwood et al ‘Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice’ J Sherwood ESMO open 3 (1), e000294, 2018 | | 2018 |
| Pre-analytics optimization of non-invasive plasma specimens to improve KRAS mutation (KRASm) detection in patients with non-small cell lung cancer (NSCLC). J Sherwood, A Sharpe, C Corcoran, H Brown, M Musilova, J Walker, ... Journal of Clinical Oncology 33 (5s), 2015 | | 2015 |
| Ultrasensitive MALDI-TOF Based Mutation Detection Is More Sensitive than ARMS in Purified Cell-Free Plasma DNA from Melanoma Patients MJ Mosko, AA Nakorchevsky, E Flores, JE Morten, JL Sherwood, ... JOURNAL OF MOLECULAR DIAGNOSTICS 16 (6), 783-783, 2014 | | 2014 |
| Analysis of mutations in formalin-fixed paraffin-embedded (FFPE) tumor samples from two phase II clinical trials using a Sequenom-based approach. M Orr, J Sherwood, G McWalter, E Donald Journal of Clinical Oncology 30 (15_suppl), 1548-1548, 2012 | | 2012 |
Munir PirmohamedUniversity of LiverpoolAdresse e-mail validée de liv.ac.uk
